Evaluation of HER2 Expression and Clinico-pathological Parameters in Gastric Adenocarcinoma: An Observational Study
- 1. Associate Professor, Department of Pathology, MNR Medical College and Hospital, Sangareddy, Telangana, India
- 2. Assistant Professor, Department of Pathology, MNR Medical College and Hospital, Sangareddy, Telangana, India
Description
Introduction: Gastric cancer remains the third most prevalent cancer-related death worldwide. Over expression of the human epidermal growth factor-2 (HER2) is linked to poor prognosis and therapeutic responsiveness. For patients with advanced gastric and gastroesophageal junction cancer that is HER2-positive, the combination of chemotherapy and the anti-HER2 monoclonal antibody Tratuzumab is now recommended. The present study was designed to assess the HER2 over expression in the cases with gastric adenocarcinoma. Materials and Methods: Forty-eight cases diagnosed histopathologically as adenocarcinoma of gastroesophageal junction and stomachabove 18 years of age. Specimens were undergone histopathological examination and assessed adenocarcinomas according to WHO classification and specimens were allowed for immunohistochemistry. Results: Tumors at pyloric canal (37.5%) were frequent and tubular adenocarcinoma (58.33%) was frequently observed tumor type. Out of 18 participants undergone immune histochemistry showed grade 0 and 1+ in 3 cases (44%), grade 2+ was observed in 3 cases (17%) and grade 3+ was seen in 7 cases (39%). Conclusion: HER2 overexpression was found in seven cases. Greater knowledge of HER2 expression in gastric cancer may influence new treatment modalities and improve staging techniques.
Abstract (English)
Introduction: Gastric cancer remains the third most prevalent cancer-related death worldwide. Over expression of the human epidermal growth factor-2 (HER2) is linked to poor prognosis and therapeutic responsiveness. For patients with advanced gastric and gastroesophageal junction cancer that is HER2-positive, the combination of chemotherapy and the anti-HER2 monoclonal antibody Tratuzumab is now recommended. The present study was designed to assess the HER2 over expression in the cases with gastric adenocarcinoma. Materials and Methods: Forty-eight cases diagnosed histopathologically as adenocarcinoma of gastroesophageal junction and stomachabove 18 years of age. Specimens were undergone histopathological examination and assessed adenocarcinomas according to WHO classification and specimens were allowed for immunohistochemistry. Results: Tumors at pyloric canal (37.5%) were frequent and tubular adenocarcinoma (58.33%) was frequently observed tumor type. Out of 18 participants undergone immune histochemistry showed grade 0 and 1+ in 3 cases (44%), grade 2+ was observed in 3 cases (17%) and grade 3+ was seen in 7 cases (39%). Conclusion: HER2 overexpression was found in seven cases. Greater knowledge of HER2 expression in gastric cancer may influence new treatment modalities and improve staging techniques.
Files
IJPCR,Vol15,Issue7,Article91.pdf
Files
(464.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:ea8a4f9b51e0580e7994aac441442524
|
464.2 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-05-25
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue7,Article91.pdf
- Development Status
- Active
References
- 1. Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. World J Gastroenterol. 2014; 20:4483–90. 2. GLOBOCON Project. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. IARC (International Agency for Research on Cancer) /WHO. 2015. 3. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358:36–46. 4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol. 2006; 24:4991–7. 5. Chua, Terence C, and Neil D Merrett. Clinicopathologic factors associated with HER2- positive gastric cancer and its impact on survival outcomes--a systematic review. International journal of cancer vol. 130,12 (2012): 2845-56. 6. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016; 22:4619– 25. 7. Roy PS, Nyodu T, Hazarika M, Saikia BJ, Bhuyan C, Inamdar A, Nyuthe CW, Borthakur B, Sharma JD. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population. Asian Pac J Cancer Prev. 2019;20(4):1139-1145. 8. Fujita, Tetsuji. Trastuzumab for gastric cancer treatment. Lancet (London, England). 2010; 376:9754: 1735; 1735-6. 9. Bang, Yung-Jue et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2010; 376:9742: 687-97. 10. Nagtegaal, Iris D et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2): 182-188. 11. Suchitra S, Panigrahi R, Rath J, Senapati U. HER2/neu expression in gastric carcinoma and its association with Helicobacter pylori infec-tion and other clinicopathological parameters. Indian J Pathol Oncol. 2020;7(3):447-451. 12. Alvarado-Cabrero I, Gil-Hernández S, RuelasPerea A, Villaverde-Rodríguez D, MontesOchoa JR, Medrano-Guzmán R. Evaluation porinmunohistoquímica de la expresión del HER2 encáncergástrico. Estudioclínicopatológico de 93 casos. Cir Cir. 2017; 85:504– 509. 13. Jung JE, OssamuIoshii S. Immunohistochemical assessment of HER2 expression in gastric cancer in a cohort of 118 Brazilian patients. J Bras Pathol Lab Med. 2013; 49:361-7. 14. Beltran-Garate B, Yabar Berrocal A. Expresión de HER2 en cancer gastricoen Peru. Rev Gastroenterol Peru. 2010; 30:324-7. 15. Garcia-Ramirez CA, Uribe-Perez CJ, NinoVargas P, Salazar Radi DS, Vasquez- Pinto LE. Expresion de HER2/neu encarcinomagastricoenel area metropolitana de Bucaramanga enel period 2006-2009. Méd UIS. 2013; 26:21-8. 16. Shitara K, Yatabe Y, Matsuo K, et al. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer. 2013; 16:261–7. 17. Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23:2656–62. 18. Hong-Bo Wang, MM, Xiao-Feng Liao, MD, Jian Zhang, MM. Clinicopathological factors associated with HER2-positive gastric cancer A meta-analysis. Medicine. 2017; 96: 44 (e8437). 19. Lei, Yu-Ying et al. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World Journal of surgical oncology. 2017;15: 68. 20. De Carli, Diego Michelon et al. Immunohistochemical expression of HER2 in adenocarcinoma of the stomach. Arquivos de gastroenterologia. 2015;52(2): 152-5.